Please login to the form below

Not currently logged in
Email:
Password:

WuXi PharmaTech hires for three senior level positions

WuXi PharmaTech hires new staff to three key senior level positions, including executive vice-president of operations, vice-president of toxicology and vice-president of finance

WuXi PharmaTech, a Chinese-headquartered provider of pharmaceutical R&D outsourcing services, has made hires to three key senior level positions, including executive vice-president of operations, vice-president of toxicology and vice-president of finance.

Mr Edward Hu will serve as WuXi PharmaTech's executive vice-president of operations, and will report directly to Dr Ge Li, who is WuXi's chairman and CEO. Hu brings an extensive experience in operations and financial management. Before his appointment with WuXi PharmaTech, he was the senior vice-president and COO of Tanox, where he managed operations, finance, IT, project management and strategic planning. Hu has also held management positions at Biogen Idec and Merck.

Dr Victor H Chen will serve as vice-president and head of toxicology at SuZhou PharmaTech and will report directly to Dr Ge Li, chairman and CEO of the company.

Chen will work closely with Dr Lijie Fu, head of operations at SuZhou PharmaTech to further enhance WuXi's capability and capacity in Toxicology services.

Prior to joining WuXi PharmaTech, Dr. Chen held the position of director of toxicology for ImClone Systems. He has previously held positions at Pfizer and Bristol-Myers Squibb, as well as at the University of Hawaii.

Reporting to Mr Benson Tsang, WuXI's CFO, Christine Lu-Wong has been appointed as vice-president of finance. Lu-Wong has held various finance positions at multi-national companies, such as Hewlett-Packard and Sun Microsystems. Prior to joining WuXi PharmaTech, Lu-Wong consulted many companies in San Jose, California including Google and Altera.

14th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics